Literature DB >> 16915542

Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.

M Schütt1, W Kern, U Krause, P Busch, A Dapp, R Grziwotz, I Mayer, J Rosenbauer, C Wagner, A Zimmermann, W Kerner, R W Holl.   

Abstract

Blood glucose measurements are generally accepted components of a modern diabetes self-management. The value of self-monitoring of blood glucose (SMBG) is, however, discussed controversially and only a few studies addressed the efficacy of SMBG under real-life conditions so far. In order to investigate whether the frequency of SMBG is related to long-term metabolic control, data from the DPV-Wiss-database, a standardized,prospective, computer-based documentation of diabetes care and outcome, were analyzed for patients with type 1(n = 19,491) and type 2 (n = 5,009) diabetes from 191 centers in Germany and Austria. Local HbA1c reference ranges were mathematically adjusted to the DCCT reference. For each patient, data from the most recent year of diabetes care were used. On average,patients with type 1 diabetes performed 4.4 blood glucose measurements/day. Corrected for age, gender, diabetes duration,on intensified (>or=4 daily injections or CSII) therapy (HbA1c reduction of 0.32% for one additional SMBG/day) compared to patients on conventional (1-3 daily injections) therapy(HbA1c-reduction of 0.16% for one additional SMBG/day). In 2,021 patients with insulin-treated type 2 diabetes (2.7 measurements/day), more frequent SMBG was associated with better metabolic control (HbA1c-reduction of 0.16% for one additionalSMBG/day, p < 0.0001), while in 2,988 patients on OAD or diet alone (2.0 measurements/day), more frequent blood glucose measurements were associated with higher HbA1c-levels(HbA1c-increase of 0.14% for one additional SMBG/day,p < 0.0001). These data indicate that more frequent SMBG are associated with better metabolic control in both, patients with type 1 and insulin-treated type 2 diabetes. Since no benefit ofSMBG on metabolic control was found in patients with type 2 diabetes on OAD or diet alone, SMBG should primarily be recommended for those patients with suboptimal metabolic control whereas the benefit of SHBG in non-insulin-treated patients with adequate HbA1c-levels remains uncertain.insulin therapy and center difference, the SMBG frequency was associated with better metabolic control (HbA1c-reduction of0.26% for one additional SMBG/day, p < 0.0001). HbA1c-reduction with higher frequency of SMBG was more pronounced in patients Blood glucose measurements are generally accepted components of a modern diabetes self-management. The value of self-monitoring of blood glucose (SMBG) is, however, discussed controversially and only a few studies addressed the efficacy of SMBG under real-life conditions so far. In order to investigate whether the frequency of SMBG is related to long-term metabolic control, data from the DPV-Wiss-database, a standardized,prospective, computer-based documentation of diabetes care and outcome, were analyzed for patients with type 1(n = 19,491) and type 2 (n = 5,009) diabetes from 191 centers in Germany and Austria. Local HbA1c reference ranges were mathematically adjusted to the DCCT reference. For each patient, data from the most recent year of diabetes care were used. On average,patients with type 1 diabetes performed 4.4 blood glucose measurements/day. Corrected for age, gender, diabetes duration,insulin therapy and center difference, the SMBG frequency wasassociated with better metabolic control (HbA1c-reduction of 0.26% for one additional SMBG/day, p < 0.0001). HbA1c-reduction with higher frequency of SMBG was more pronounced in patients on intensified (>or= 4 daily injections or CSII) therapy (HbA1c reduction of 0.32% for one additional SMBG/day) compared to patients on conventional (1-3 daily injections) therapy(HbA1c-reduction of 0.16% for one additional SMBG/day). In 2,021 patients with insulin-treated type 2 diabetes (2.7 measurements/day), more frequent SMBG was associated with better metabolic control (HbA1c-reduction of 0.16% for one additionalSMBG/day, p < 0.0001), while in 2,988 patients on OAD or diet alone (2.0 measurements/day), more frequent blood glucose measurements were associated with higher HbA1c-levels(HbA1c-increase of 0.14% for one additional SMBG/day, p < 0.0001). These data indicate that more frequent SMBG are associated with better metabolic control in both, patients with type 1 and insulin-treated type 2 diabetes. Since no benefit of SMBG on metabolic control was found in patients with type 2 diabetes on OAD or diet alone, SMBG should primarily be recommended for those patients with suboptimal metabolic control whereas the benefit of SHBG in non-insulin-treated patients with adequate HbA1c-levels remains uncertain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16915542     DOI: 10.1055/s-2006-924152

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  65 in total

1.  Glycemic control in Iranian children with type 1 diabetes mellitus: effect of gender.

Authors:  Aria Setoodeh; Fereydoun Mostafavi; Tina Hedayat
Journal:  Indian J Pediatr       Date:  2011-12-03       Impact factor: 1.967

2.  Interindividual and intraindividual variations in postprandial glycemia peak time complicate precise recommendations for self-monitoring of glucose in persons with type 1 diabetes mellitus.

Authors:  Mette Dencker Johansen; Irene Gjerløv; Jens Sandahl Christiansen; Ole K Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

3.  Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.

Authors:  Richard M Bergenstal; Mary Johnson; Rebecca Passi; Anuj Bhargava; Natalie Young; Davida F Kruger; Eran Bashan; Stanley G Bisgaier; Deanna J Marriott Isaman; Israel Hodish
Journal:  Lancet       Date:  2019-02-23       Impact factor: 79.321

4.  6(th) Annual Symposium on Self-Monitoring of Blood Glucose (SMBG) applications and beyond, April 25-27, 2013, Riga, Latvia.

Authors:  Aus Alzaid; Christof Schlaeger; Rolf Hinzmann
Journal:  Diabetes Technol Ther       Date:  2013-09-28       Impact factor: 6.118

5.  Sources of glycemic variability--what type of technology is needed?

Authors:  Jonas Kildegaard; Toke Folke Christensen; Ole Kristian Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2009-07-01

Review 6.  Lancing: quo vadis?

Authors:  Lutz Heinemann; Dirk Boecker
Journal:  J Diabetes Sci Technol       Date:  2011-07-01

7.  Self monitoring of blood glucose in type 2 diabetes: longitudinal qualitative study of patients' perspectives.

Authors:  Elizabeth Peel; Margaret Douglas; Julia Lawton
Journal:  BMJ       Date:  2007-08-30

8.  [Blood glucose self monitoring].

Authors:  Thomas C Wascher
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

9.  Self-monitoring of blood glucose in type 2 diabetes: an inter-country comparison.

Authors: 
Journal:  Diabetes Res Clin Pract       Date:  2008-11-07       Impact factor: 5.602

10.  Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.

Authors:  Denis Raccah; Véronique Sulmont; Yves Reznik; Bruno Guerci; Eric Renard; Hélène Hanaire; Nathalie Jeandidier; Marc Nicolino
Journal:  Diabetes Care       Date:  2009-09-18       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.